Lidocaine patch transdermal - MEDRx

Drug Profile

Lidocaine patch transdermal - MEDRx

Alternative Names: Lidocaine Patch 20% - MEDRx; MRX 5LBT

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator MEDRx
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Neuropathic pain

Most Recent Events

  • 26 Sep 2016 Pharmacokinetics data from a phase I trial in Neuropathic pain (In volunteers) presented at the World Congress on Pain (WCP-2016)
  • 31 May 2016 MEDRx completes a phase I trial in Neuropathic pain (In volunteers) in Japan
  • 01 May 2016 Phase-I clinical trials in Neuropathic pain (In volunteers) in Japan (Transdermal) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top